Related Experiment Video
Updated: Feb 11, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Allosteric modulation of the farnesoid X receptor by a small molecule
Matthias Gabler1, Jan Kramer1, Jurema Schmidt1
1Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Max-von-Laue-Str. 9, D-60438, Frankfurt, Germany.
Abstract:
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders. FXR agonists have revealed efficacy in treating non-alcoholic steatohepatitis (NASH), diabetes and dyslipidemia. Here we characterize imatinib as first-in-class allosteric FXR modulator and report the development of an optimized descendant that markedly promotes agonist induced FXR activation in a reporter gene assay and FXR target gene expression in HepG2 cells. Differential effects of imatinib on agonist-induced bile salt export protein and small heterodimer partner expression suggest that allosteric FXR modulation could open a new avenue to gene-selective FXR modulators.
Insights
This study identifies imatinib as a novel allosteric modulator of the farnesoid X receptor (FXR). This discovery offers a new approach for developing gene-selective FXR modulators for metabolic diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The farnesoid X receptor (FXR) is a bile acid-activated transcription factor crucial for metabolic regulation.
- FXR agonists show therapeutic potential for non-alcoholic steatohepatitis (NASH), diabetes, and dyslipidemia.
Purpose of the Study:
- To characterize imatinib as a first-in-class allosteric FXR modulator.
- To develop an optimized imatinib derivative with enhanced FXR activity.
Main Methods:
- Reporter gene assays to assess FXR activation.
- Analysis of FXR target gene expression in HepG2 cells.
- Evaluation of imatinib's differential effects on specific FXR target genes.
Main Results:
- Imatinib was identified as an allosteric FXR modulator.
- An optimized imatinib derivative significantly enhanced agonist-induced FXR activation.
- Differential modulation of bile salt export protein and small heterodimer partner expression was observed.
Conclusions:
- Allosteric FXR modulation represents a novel therapeutic strategy.
- This approach may lead to the development of gene-selective FXR modulators.
- Imatinib and its derivatives offer a promising new class of compounds for metabolic disorders.
Related Concept Videos
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Internal Receptors
Allosteric Regulation
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...

